Innovative Approaches in Regulatory Affairs: Leveraging Artificial Intelligence and Machine Learning for Efficient Compliance and Decision-Making.
Journal:
The AAPS journal
PMID:
39776314
Abstract
Artificial Intelligence (AI) and AI-driven technologies are transforming industries across the board, with the pharmaceutical sector emerging as a frontrunner beneficiary. This article explores the growing impact of AI and Machine Learning (ML) within pharmaceutical Regulatory Affairs, particularly in dossier preparation, compilation, documentation, submission, review, and regulatory compliance. By automating time-intensive tasks, these technologies streamline workflows, accelerate result generation, and shorten the product approval timeline. However, despite their immense potential, AI and ML also introduce new challenges. Issues such as AI software validation, data management security and privacy, potential biases, ethical concerns, and change management requirements must be addressed. This review highlights current AI-based tools actively used by regulatory professionals such as DocShifter, Veeva Vault, RiskWatch, Freyr SubmitPro, Litera Microsystems, cortical.io etc., examines both the benefits and obstacles of integrating these advanced systems into regulatory practices. Given the rapid pace of technological innovation, the article underscores the need for proactive collaboration with regulatory bodies to manage these developments. It also stresses the importance of adapting to evolving regulatory frameworks and embracing new technologies. Although regulatory agencies like the United Sates Food and Drug Administration (USFDA), European Medicines Agency (EMA), and Medicines and Healthcare products Regulatory Agency (MHRA) are working on guidelines for AI and ML adoption, clear, standardized protocols are still in the works. While the journey ahead may be complex, the integration of AI promises to fundamentally reshape regulatory processes and accelerate the approval of safe, effective pharmaceutical products.